

Strides and Orbicular enter into strategic partnership to develop range of nasal sprays

04 May 2023 | News

Strides to launch the products globally through its commercial arms



Bengaluru-based Strides Pharma Science and Orbicular Pharmaceutical Technologies, in Hyderabad, have entered into a strategic partnership to develop, manufacture and commercialise nasal sprays for the global markets.

Orbicular, a speciality pharmaceutical company focused on research and product development, will use its expertise in drug delivery and formulation to develop nasal sprays for global markets. The company has deployed a thorough product design approach to ensure the nasal sprays are robust, following "Quality-by-Design" principles.

Strides will commercialise these nasal sprays across the markets using its commercial engine in the US, Europe, and several other markets. The products will be manufactured at company's state-of-the-art Chestnut Ridge, New York facility.

The facility has comprehensive capabilities for nasal spray manufacturing in the unit dose and multi-dose format, including for controlled substances. The site has been in continuous operation for four decades with approval from USFDA and Drug Enforcement Administration (DEA) with a strong compliance track record. Strides acquired this facility in October 2021 from Endo Inc.

The partnership will commercialise four nasal sprays with a combined Global IQVIA market size in excess of \$400 million.